Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1

A Randomized, Double-blind, Placebo-controlled, Parallel-design Clinical Study to Evaluate the Irritable Bowel Syndrome Symptoms Improving Effect and Safety of Lactobacillus Plantarum APsulloc 331261(GTB1)

This study was conducted to investigate the effects of daily supplementation of L. plantarum APsulloc 331261(GTB1TM) on improvement of IBS symptoms.

Inclusion Criteria:

• Male and female subjects older than 19 years old
• Diagnosed case of IBS using Rome IV criteria
• Who had type 6 or 7 stools according to the BSFS on at least 2 weeks ≥ 25%
• Who voluntarily agreed to participate in the study and signed an informed consent form

Exclusion Criteria:

• Who had been ingesting products containing probiotics or prebiotics in the 4 weeks preceding entry into the trial
• Who had antibiotic agents during the 4 weeks prior to study entry
• Women who is pregnant /breast-feeding, or who has childbearing potential and does not use available contraceptives
• Who is determined ineligible for study participation by investigators for any other reasons